Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
Healthcare
$18.31 +0.58%
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
52W Low $14.85High $23.00
Volume 0.68M
Average 0.41M
SPTX Total Current Liabilities
All obligations due within one year.
No reported Total Current Liabilities figures are available to summarize.
Total Current Liabilities history
Currency unavailable · from the balance sheet
No Total Current Liabilities data reported for this period type.
Total Current Liabilities vs competitors
How SPTX compares with its peers on the latest reported figures
SPTX Competitors
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $135.58M USD | +30.5% | +16.7% | 31.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $30.12M USD | +6.1% | +11.0% | 19.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $17.9M USD | +90.7% | +125.4% | 3.6% |
| Mar 2026 | $14.28M USD | +10.0% | +8.8% | 3.4% | |
| Mar 2026 | $11.82M USD | +19.1% | +22.6% | 4.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $10.91M USD | +179.2% | +151.3% | 2.8% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $6.66M USD | -25.6% | +8.9% | 2.5% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +19.1% | +16.7% | 3.6% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Currency unavailable
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.